AMPH Stock Overview
A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 4/6 |
Past Performance | 6/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Amphastar Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$43.46 |
52 Week High | US$67.66 |
52 Week Low | US$38.43 |
Beta | 0.85 |
1 Month Change | 8.19% |
3 Month Change | -16.28% |
1 Year Change | -1.43% |
3 Year Change | 124.72% |
5 Year Change | 115.36% |
Change since IPO | 334.17% |
Recent News & Updates
Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Recent updates
Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
Jun 10Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio
May 13I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease
Apr 23These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Feb 13Amphastar Pharma: A Well-Run, Diversified Mid Cap
Jan 26Should You Be Adding Amphastar Pharmaceuticals (NASDAQ:AMPH) To Your Watchlist Today?
Jan 08Shareholder Returns
AMPH | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 2.4% | 1.9% | 1.2% |
1Y | -1.4% | 16.7% | 27.7% |
Return vs Industry: AMPH underperformed the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: AMPH underperformed the US Market which returned 27.7% over the past year.
Price Volatility
AMPH volatility | |
---|---|
AMPH Average Weekly Movement | 5.8% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: AMPH's share price has been volatile over the past 3 months.
Volatility Over Time: AMPH's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 1,761 | Jack Zhang | www.amphastar.com |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures.
Amphastar Pharmaceuticals, Inc. Fundamentals Summary
AMPH fundamental statistics | |
---|---|
Market cap | US$2.05b |
Earnings (TTM) | US$154.69m |
Revenue (TTM) | US$676.21m |
13.7x
P/E Ratio3.1x
P/S RatioIs AMPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AMPH income statement (TTM) | |
---|---|
Revenue | US$676.21m |
Cost of Revenue | US$308.83m |
Gross Profit | US$367.38m |
Other Expenses | US$212.69m |
Earnings | US$154.69m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 3.16 |
Gross Margin | 54.33% |
Net Profit Margin | 22.88% |
Debt/Equity Ratio | 88.3% |
How did AMPH perform over the long term?
See historical performance and comparison